European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendiaโs MammaPrint Test with Highest Level 1A Clinical Evidence
MammaPrintยฎ is the first and only multigene test to receive Read More
German Gynecological Oncology Group (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence
2017 Guidelines of the AGO Breast Committee acknowledges Agendiaโs MammaPrint Read More
Agendia Co-Founder Laura van โt Veer Wins European Cancer Organization Clinical Research Award
Significant clinical benefit of Agendiaโs MammaPrintยฎ test and other advances Read More
New Data Shows that MammaPrint Substantially Impacts how Breast Cancer Patients in Germany are Treated
PRIMe trial included 452 women at 27 centers in Germany, Read More
Three New Studies Presented at San Antonio Breast Cancer Symposium Further Demonstrate Value of MammaPrint and BluePrint in Individualizing Treatment for Breast Cancer Patients
Long-term follow-up of early-stage breast cancer patients shows significant difference Read More
Agendia Responds to IQWiG Assessment for Reimbursement of Gene Expression-based Breast Cancer Recurrence Tests
IRVINE, CA and AMSTERDAM, 5 December 2016 โ Agendia, Inc., Read More
Agendiaโs MammaPrint and BluePrint Tests Highlighted in Multiple Presentations at the 2016 San Antonio Breast Cancer Symposium, Adding Further Clinical Utility
Agendia will also host two additional educational opportunities for physicians Read More
Agendiaโs proven breast cancer recurrence assay, MammaPrint, now available in the Middle East
Agendia signs partnership agreement with Cryogene and Mist for Middle Read More
Agendia Announces the Award of a New Category 1 CPT Code from the American Medical Association for the MammaPrint 70-Gene Breast Cancer Recurrence Assay
The company also announces new patient awareness platform to help Read More
Agendia Expands its Business Activities in Germany
The โBRIDGEโ initiative offers German patients free access to Agendiaโs Read More
